90
Participants
Start Date
October 8, 2024
Primary Completion Date
August 12, 2026
Study Completion Date
December 12, 2026
ACR-2316
ACR-2316 is an experimental drug
RECRUITING
Montefiore Medical Centre, The Bronx
RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
RECRUITING
Next Virginia, Fairfax
RECRUITING
Carolina BioOncology Institute, Huntersville
RECRUITING
Florida Cancer Specialist, Sarasota
RECRUITING
Tennesse Oncology, Franklin
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
NEXT Oncology, San Antonio
RECRUITING
Denver Health One, Denver
RECRUITING
HonorHealth Cancer Care, Phoenix
RECRUITING
Precision NextGen Oncology & Research Center, Beverly Hills
RECRUITING
Hoag Memorial Hospital Presbyterian, Newport Beach
RECRUITING
Beth Israel Deaconess Medical Center, Boston
RECRUITING
Rhode Island Hospital, Providence
Lead Sponsor
Acrivon Therapeutics
INDUSTRY